Hemab is a clinical-stage biotech company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Based in Cambridge, Massachusetts and Copenhagen, Denmark, Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company’s strategic guidance, Hemab 1-2-5, targets the development of 5 clinical assets by 2025 to deliver long-awaited innovation for patients with high unmet need blood clotting disorders like Glanzmann Thrombasthenia, factor VII deficiency, Bernard Soulier Syndrome, Von Willebrand Disease and other serious disorders. Learn more at hemab.com.

Novo Holdings

RA Capital Management

HealthCap

Deep Track Capital

Rock Springs Capital

Invus

Access Biotechnology

Avoro Ventures

Maj Invest Equity

Hemab Therapeutics

To mark the end of #BleedingDisordersAwarenessMonth, we acknowledge the impacts people living with #GlanzmannThrombasthenia experience beyond frequent and unpredictable bleeding episodes. Many also report significant social isolation, anxiety, depression, fatigue, and more.
 
We are advancing the first prophylactic treatment for GT to reimagine the standard of care.

Interested in learning more about our commitment to #RedefineLife with #RareBleeding? Visit www.hemab.com.
 
#BDAM24 #BleedingDisorders

In our ongoing efforts to raise awareness during #BleedingDisordersAwarenessMonth, Hemab recognizes the heavy toll disorders such as Glanzmann Thrombasthenia (GT) can have on quality of life. Did you know that 1 in 450,000 people are impacted by GT? For those living with GT, 87% report having one or more bleeding events per week.
 
We are committed to developing the first prophylactic treatment for GT and other rare bleeding disorders to #RedefineLife with #RareBleeding.
 
Learn more: www.hemab.com.
 
#BleedingDisorders #BDAM24 #Biotech

As part of #BleedingDisordersAwarenessMonth, we’re highlighting the under-recognized bleeding and clotting disorders that affect people worldwide. Factor VII Deficiency is one such disorder that impacts approximately 1 in 3-500,000 people of all ages. Currently, there are no preventative treatment options available, meaning patients and providers have to react to bleeds rather than managing them for the long term.
 
As part of our mission to help #RedefineLife with #RareBleeding, we are advancing a new class of treatments to transform the standard of care. Learn more at hemab.com.
 
#BDAM24 #FVIID #BleedingDisorders #ClottingDisorders #Biotech

Data Deep Dive: Glanzmann thrombasthenia (GT) is a severe bleeding disorder characterized by a defect in platelet aggregation. Preclinical data published in #NatureCVR suggests our lead asset, HMB-001, in the presence of FVIIa, reduces time to platelet aggregation; achieves maximal aggregation; and does not drive aggregation in the absence of FVIIa, supporting its potential as a prophylactic solution for #GlanzmannThrombasthenia.

Read the paper here: https://lnkd.in/eV4Qv-up

#Data #Biotech #RareBleeding

This #BleedingDisordersAwarenessMonth, Hemab is bringing attention to the experiences of patients, caregivers, and loved ones affected by bleeding and clotting disorders as we advance treatments to help them #RediscoverLife with #RareBleeding.

Despite experiencing serious, life-threatening bleeds, most people living with these disorders have no preventative treatments to turn to, significantly impacting their ability to go to work and school, participate in hobbies and activities, and engage with their communities. Follow along as we share more data and insights this month.
 
Learn more about our scientific approach to finding and serving patients with high unmet need at hemab.com.

And follow the National Bleeding Disorders Foundation and their efforts here: https://lnkd.in/g-7xHy7
 
#BDAM24 #BleedingDisorders #GlanzmannThrombasthenia

Eikon Therapeutics is a potential competitor to Hemab ApS in the biotech industry.

Eikon Therapeutics

Interius BioTherapeutics is a potential competitor to Hemab ApS in the biotech industry.

Interius BioTherapeutics

Bright Peak Therapeutics is a potential competitor to Hemab ApS in the biotech industry.

Bright Peak Therapeutics

Anthos Therapeutics is a potential competitor to Hemab ApS in the biotech industry.

Anthos Therapeutics

PlateletBio is a potential competitor to Hemab ApS in the biotech industry.

PlateletBio

X-37 is a potential competitor to Hemab ApS in the biotech industry.

X-37

Varmx is a potential competitor to Hemab ApS in the biotech industry.

Varmx

TargED is a potential competitor to Hemab ApS in the biotech industry.

TargED

AbFero Pharmaceuticals is a potential competitor to Hemab ApS in the biotech industry.

AbFero Pharmaceuticals

LUNAC Therapeutics is a potential competitor to Hemab ApS in the biotech industry.

LUNAC Therapeutics

Ona Therapeutics is a potential competitor to Hemab ApS in the biotech industry.

Ona Therapeutics

Delpor is a potential competitor to Hemab ApS in the biotech industry.

Delpor

Ab Studio is a potential competitor to Hemab ApS in the biotech industry.

Ab Studio

Metabolon is a potential competitor to Hemab ApS in the biotech industry.

Metabolon

Acticor Biotech is a potential competitor to Hemab ApS in the biotech industry.

Acticor Biotech

uniQure is a potential competitor to Hemab ApS in the biotech industry.

uniQure

Spark is a potential competitor to Hemab ApS in the biotech industry.

Spark

Hemab ApS is a company that provides information about its cookie policy and respects the privacy of visitors to its website.

news impact assignment basic	general	May 6, 2024 7:56 AM	d7e16dc6
public peers	general	May 6, 2024 7:56 AM	bcc6183e
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 6, 2024 7:56 AM	67825b45
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 6, 2024 7:56 AM	8dd944e0
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 6, 2024 7:56 AM	8871b329
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:HEMAB

Hemab ApS